The Quantellect read.As of Nov 19, 2026, 4 active firms cover ANI Pharmaceuticals Inc: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $85.00 to $119.00, a moderate spread. The average target of $98.50 sits 38% above the current $71.48. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 27% this year and 11% next, consensus EPS building from about $1.71 next quarter toward $10.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$98.50
+37.8% upside
Average target across 4 active firms as of Nov 19, 2026 vs $71.48 current
Highest Target$119.00
Average Target$98.50
Lowest Target$85.00
Detailed analyst forecasts for ANIP
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate ANIP a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ANIP EPS & revenue forecast
EPS · NEXT QUARTER
$1.71
Range $1.12 – $2.25 · 6 analysts · -16% YoY
Next period, 6 analysts expect ANI Pharmaceuticals Inc to earn $1.71 a share (range $1.12 – $2.25), versus $2.05 a year earlier. Full-year consensus is $9.51, growing to $10.20 the year after.
REVENUE · NEXT QUARTER
$257.4M
Range $229.3M – $283.0M · 6 analysts · +31% YoY
Revenue is expected to reach $257.4M (range $229.3M – $283.0M), +31.0% year-over-year. Full-year consensus is $1.1B, rising to $1.2B next year.
Top analysts covering ANI Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANIP.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$111.00+55.3% to target
Overall win rate
50%
+ Follow
#2
Vamil Divan
Guggenheim · Rank #211
Buy
$119.00+66.5% to target
Overall win rate
48%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$94.00+31.5% to target
Overall win rate
54%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$121.00+69.3% to target
Overall win rate
38%
+ Follow
#5
GN
Gary Nachman
Canaccord Genuity
Neutral
$90.00+25.9% to target
Coverage
—
+ Follow
ANIP stock forecast FAQ
What is ANIP's average 12-month price target?+
The 4 active firms with a live target average $98.50 for ANI Pharmaceuticals Inc over the next 12 months, ranging from a $119.00 high to a $85.00 low, as of Nov 19, 2026.
Is ANIP stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ANIP?+
The Street-high target is $119.00 (Guggenheim), and the Street-low is $85.00 (Oppenheimer). The average of all 4 active-firm targets is $98.50.
How many active Wall Street firms cover ANIP?+
4 active firms have a recognized rating on ANI Pharmaceuticals Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ANIP?+
Among analysts who currently cover ANIP, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $111.00 target.
What is ANI Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $1.71 per share (range $1.12 – $2.25) across 6 analysts. Full-year EPS is projected at $9.51, rising to $10.20 the following year.
How much revenue is ANI Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $257.4M (range $229.3M – $283.0M). Full-year revenue is projected at $1.1B, growing to $1.2B next year.
Have analysts been upgrading or downgrading ANIP lately?+
As of Nov 19, 2026, 2 of 4 active firms rate ANIP a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANIP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.